186 related articles for article (PubMed ID: 16622681)
81. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
82. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
83. Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.
Lopez M; Ghidouche A; Rochas C; Godelaine D; Carrasco J; Colau D; Hames G; Montero-Julian FA; Coulie PG; Olive D
Cancer Immunol Immunother; 2016 Oct; 65(10):1177-88. PubMed ID: 27514672
[TBL] [Abstract][Full Text] [Related]
84. Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.
Atzin-Méndez JA; López-González JS; Báez R; Arenas-Del Angel MC; Montaño LF; Silva-Adaya D; Lascurain R; Gorocica P
Oncol Rep; 2016 Jan; 35(1):33-42. PubMed ID: 26498650
[TBL] [Abstract][Full Text] [Related]
85. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
Nishizaka S; Gomi S; Harada K; Oizumi K; Itoh K; Shichijo S
Cancer Res; 2000 Sep; 60(17):4830-7. PubMed ID: 10987294
[TBL] [Abstract][Full Text] [Related]
86. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
87. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
88. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Takaki T; Hiraki A; Uenaka A; Gomi S; Itoh K; Udono H; Shibuya A; Tsuji T; Sekiguchi S; Nakayama E
Int J Oncol; 1998 May; 12(5):1103-9. PubMed ID: 9538136
[TBL] [Abstract][Full Text] [Related]
89. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes.
Eifuku R; Takenoyama M; Yoshino I; Imahayashi S; So T; Yasuda M; Sugaya M; Yasumoto K
Int J Clin Oncol; 2001 Feb; 6(1):34-9. PubMed ID: 11706525
[TBL] [Abstract][Full Text] [Related]
90. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
91. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
92. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
[TBL] [Abstract][Full Text] [Related]
93. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
[TBL] [Abstract][Full Text] [Related]
94. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
[TBL] [Abstract][Full Text] [Related]
95. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
96. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
97. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
98. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
99. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer D; Grünewald TG; Klar R; Schmidt O; Wohlleber D; Rubío RA; Uckert W; Thiel U; Bohne F; Busch DH; Krackhardt AM; Burdach S; Richter GH
Oncoimmunology; 2016 Jun; 5(6):e1175795. PubMed ID: 27471654
[TBL] [Abstract][Full Text] [Related]
100. STEAP proteins: from structure to applications in cancer therapy.
Gomes IM; Maia CJ; Santos CR
Mol Cancer Res; 2012 May; 10(5):573-87. PubMed ID: 22522456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
